{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T11:11:59Z","timestamp":1782817919859,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Justus-Liebig-Universit\u00e4t Gie\u00dfen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Cardiol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Perioperative tachyarrhythmias are common in children undergoing cardiac surgery, contributing to significant mortality and morbidity. Landiolol, an ultrashort-acting beta-blocker, offers selective heart rate (HR) control in pediatric patients with tachycardia during cardiac surgery. The LANDI-cardioPed study assessed landiolol's safety and efficacy in children during cardiac surgery. The retrospective review included patients under 1\u00a0year of age with intraoperative tachycardia during cardiac surgery treated with landiolol hydrochloride (Rapibloc\u00ae) at the Pediatric Heart Center Giessen, Germany (June 2017\u2013October 2022). The primary endpoint was the proportion of patients achieving a target HR (&lt;\u2009160\u00a0bpm) by surgery end. Among 24 patients (46% neonates, 54% infants; mean weight: 4.8\u00a0kg; preexisting heart failure in 71%), 83% achieved the target HR by surgery\u2019s end, with all patients reaching it during treatment. Median HR normalization time was 4.0\u00a0min and 75% of children reached it within 18.5\u00a0min. Landiolol demonstrated good hemodynamic stability. It reduced HR by 6% from baseline while maintaining stable blood pressure and HR\/BP ratios, with no increased vasopressor use. The drug was titrated individually, with a mean initial dose of 23\u00a0\u00b5g\/kg\/min, the dose was 26\u00a0\u00b5g\/kg\/min upon reaching target HR, and the maximum dose of 49\u00a0\u00b5g\/kg\/min. The treatment duration averaged 10.5\u00a0h. Safety was favorable; three adverse events unrelated to landiolol were reported, and no dose interruptions occurred. Landiolol was effective and safe for HR control in neonates and infants with tachycardia during cardiac surgery, which aligns with current knowledge on its use in children.<\/jats:p>","DOI":"10.1007\/s00246-025-03824-6","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T15:44:32Z","timestamp":1741621472000},"page":"709-717","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Heart Rate Control with Landiolol Hydrochloride in Infants and Neonates During Cardiac Surgery"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6546-9860","authenticated-orcid":false,"given":"Matthias","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas Andreas","family":"Puschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Zajonz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Unger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Ackerl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Shatilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"issue":"6","key":"3824_CR1","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.jtcvs.2006.02.010","volume":"131","author":"JW Delaney","year":"2006","unstructured":"Delaney JW, Moltedo JM, Dziura JD, Kopf GS, Snyder CS (2006) Early postoperative arrhythmias after pediatric cardiac surgery, (in eng). J Thorac Cardiovasc Surg 131(6):1296\u20131300. https:\/\/doi.org\/10.1016\/j.jtcvs.2006.02.010","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"5","key":"3824_CR2","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s00134-007-0987-2","volume":"34","author":"JB Andreasen","year":"2008","unstructured":"Andreasen JB, Johnsen SP, Ravn HB (2008) Junctional ectopic tachycardia after surgery for congenital heart disease in children, (in eng). Intensive Care Med 34(5):895\u2013902. https:\/\/doi.org\/10.1007\/s00134-007-0987-2","journal-title":"Intensive Care Med"},{"issue":"1","key":"3824_CR3","first-page":"1","volume":"65","author":"E Cools","year":"2014","unstructured":"Cools E, Missant C (2014) Junctional ectopic tachycardia after congenital heart surgery, (in eng). Acta Anaesthesiol Belg 65(1):1\u20138","journal-title":"Acta Anaesthesiol Belg"},{"issue":"1","key":"3824_CR4","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13019-022-01830-w","volume":"17","author":"AA Elassal","year":"2022","unstructured":"Elassal AA et al (2022) Neonatal congenital heart surgery: contemporary outcomes and risk profile. J Cardiothorac Surg 17(1):80. https:\/\/doi.org\/10.1186\/s13019-022-01830-w","journal-title":"J Cardiothorac Surg"},{"issue":"5","key":"3824_CR5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1080\/14017431.2017.1337216","volume":"51","author":"J Heiberg","year":"2017","unstructured":"Heiberg J, Nyboe C, Hjortdal VE (2017) Permanent chronotropic impairment after closure of atrial or ventricular septal defect. Scandinavian Cardiovascular Journal 51(5):271\u2013276. https:\/\/doi.org\/10.1080\/14017431.2017.1337216","journal-title":"Scandinavian Cardiovascular Journal"},{"issue":"12","key":"3824_CR6","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1093\/eurheartj\/ehx687","volume":"39","author":"C Nyboe","year":"2017","unstructured":"Nyboe C, Karunanithi Z, Nielsen-Kudsk JE, Hjortdal VE (2017) Long-term mortality in patients with atrial septal defect: a nationwide cohort-study. Eur Heart J 39(12):993\u2013998. https:\/\/doi.org\/10.1093\/eurheartj\/ehx687","journal-title":"Eur Heart J"},{"key":"3824_CR7","doi-asserted-by":"publisher","first-page":"100333","DOI":"10.1016\/j.ijcchd.2022.100333","volume":"7","author":"Z Karunanithi","year":"2022","unstructured":"Karunanithi Z et al (2022) Heart rate variability is markedly abnormal following surgical repair of atrial and ventricular septal defects in pediatric patients. Int J Cardiol Congen Heart Dis 7:100333. https:\/\/doi.org\/10.1016\/j.ijcchd.2022.100333","journal-title":"Int J Cardiol Congen Heart Dis"},{"issue":"3","key":"3824_CR8","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/oxfordjournals.eurheartj.a014868","volume":"17","author":"M Malik","year":"1996","unstructured":"Malik M et al (1996) Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Eur Heart J 17(3):354\u2013381. https:\/\/doi.org\/10.1093\/oxfordjournals.eurheartj.a014868","journal-title":"Eur Heart J"},{"issue":"1","key":"3824_CR9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13019-019-0966-z","volume":"14","author":"M Sakai","year":"2019","unstructured":"Sakai M, Jujo S, Kobayashi J, Ohnishi Y, Kamei M (2019) Use of low-dose \u03b21-blocker for sinus tachycardia in patients with catecholamine support following cardiovascular surgery: a retrospective study. J Cardio Surg 14(1):145. https:\/\/doi.org\/10.1186\/s13019-019-0966-z","journal-title":"J Cardio Surg"},{"key":"3824_CR10","doi-asserted-by":"publisher","first-page":"615987","DOI":"10.1155\/2014\/615987","volume":"2014","author":"G Peretto","year":"2014","unstructured":"Peretto G, Durante A, Limite LR, Cianflone D (2014) Postoperative arrhythmias after cardiac surgery: incidence, risk factors, and therapeutic management, (in eng). Cardiol Res Pract 2014:615987. https:\/\/doi.org\/10.1155\/2014\/615987","journal-title":"Cardiol Res Pract"},{"issue":"2","key":"3824_CR11","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jtcvs.2012.01.026","volume":"144","author":"P Shamszad","year":"2012","unstructured":"Shamszad P et al (2012) Perioperative atrial tachycardia is associated with increased mortality in infants undergoing cardiac surgery. J Thorac Cardiovasc Surg 144(2):396\u2013401. https:\/\/doi.org\/10.1016\/j.jtcvs.2012.01.026","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"1","key":"3824_CR12","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1097\/pcc.0000000000002524","volume":"22","author":"JA Hagel","year":"2021","unstructured":"Hagel JA, Sperotto F, Laussen PC, Salvin JW, Bachu A, Kheir JN (2021) Shock index, coronary perfusion pressure, and rate pressure product as predictors of adverse outcome after pediatric cardiac surgery, (in eng). Pediatr Crit Care Med 22(1):e67\u2013e78. https:\/\/doi.org\/10.1097\/pcc.0000000000002524","journal-title":"Pediatr Crit Care Med"},{"issue":"Suppl D","key":"3824_CR13","doi-asserted-by":"publisher","first-page":"D34","DOI":"10.1093\/eurheartjsupp\/suac025","volume":"24","author":"X Chapalain","year":"2022","unstructured":"Chapalain X et al (2022) Short acting intravenous beta-blocker as a first line of treatment for atrial fibrillation after cardiac surgery: a prospective observational study. Eur Heart J Suppl 24(Suppl D):D34\u2013D42. https:\/\/doi.org\/10.1093\/eurheartjsupp\/suac025","journal-title":"Eur Heart J Suppl"},{"issue":"5","key":"3824_CR14","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s11936-012-0195-4","volume":"14","author":"Y Bar-Cohen","year":"2012","unstructured":"Bar-Cohen Y, Silka MJ (2012) Management of postoperative arrhythmias in pediatric patients, (in eng). Curr Treat Options Cardiovasc Med 14(5):443\u2013454. https:\/\/doi.org\/10.1007\/s11936-012-0195-4","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"02","key":"3824_CR15","first-page":"16","volume":"70","author":"AE Blank","year":"2022","unstructured":"Blank AE et al (2022) Postoperative heart rate control with esmolol in newborn cardiac surgery with cardiopulmonary bypass, (in En). Thorac Cardiovasc Surg 70(02):16","journal-title":"Thorac Cardiovasc Surg"},{"issue":"3","key":"3824_CR16","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s40265-018-0883-9","volume":"78","author":"YY Syed","year":"2018","unstructured":"Syed YY (2018) Landiolol: a review in tachyarrhythmias. Drugs 78(3):377\u2013388. https:\/\/doi.org\/10.1007\/s40265-018-0883-9","journal-title":"Drugs"},{"issue":"4","key":"3824_CR17","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00540-008-0640-4","volume":"22","author":"K Ikeshita","year":"2008","unstructured":"Ikeshita K et al (2008) Landiolol has a less potent negative inotropic effect than esmolol in isolated rabbit hearts, (in eng). J Anesth 22(4):361\u2013366. https:\/\/doi.org\/10.1007\/s00540-008-0640-4","journal-title":"J Anesth"},{"issue":"1","key":"3824_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1124\/jpet.116.232884","volume":"359","author":"S Nasrollahi-Shirazi","year":"2016","unstructured":"Nasrollahi-Shirazi S, Sucic S, Yang Q, Freissmuth M, Nanoff C (2016) Comparison of the \u03b2-adrenergic receptor antagonists landiolol and esmolol: receptor selectivity, partial agonism, and pharmacochaperoning actions, (in eng). J Pharmacol Exp Ther 359(1):73\u201381. https:\/\/doi.org\/10.1124\/jpet.116.232884","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"3824_CR19","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1007\/s00246-021-02653-7","volume":"42","author":"A Ashida","year":"2021","unstructured":"Ashida A et al (2021) Safety and efficacy of landiolol hydrochloride in children with tachyarrhythmia of various etiologies, (in eng). Pediatr Cardiol 42(8):1700\u20131705. https:\/\/doi.org\/10.1007\/s00246-021-02653-7","journal-title":"Pediatr Cardiol"},{"key":"3824_CR20","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-21-0967","author":"K Sagawa","year":"2022","unstructured":"Sagawa K et al (2022) Control of heart rate in infant and child tachyarrhythmia with reduced cardiac function using landiolol (HEARTFUL)- results of a prospective, multicenter, uncontrolled clinical study. Circ J. https:\/\/doi.org\/10.1253\/circj.CJ-21-0967","journal-title":"Circ J"},{"issue":"5","key":"3824_CR21","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/j.athoracsur.2013.01.057","volume":"95","author":"C Tokunaga","year":"2013","unstructured":"Tokunaga C et al (2013) Effects of landiolol hydrochloride on intractable tachyarrhythmia after pediatric cardiac surgery, (in eng). Ann Thorac Surg 95(5):1685\u20131688. https:\/\/doi.org\/10.1016\/j.athoracsur.2013.01.057","journal-title":"Ann Thorac Surg"},{"issue":"9770","key":"3824_CR22","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/s0140-6736(10)62226-x","volume":"377","author":"S Fleming","year":"2011","unstructured":"Fleming S et al (2011) Normal ranges of heart rate and respiratory rate in children from birth to 18 years of age: a systematic review of observational studies, (in eng). Lancet 377(9770):1011\u20131018. https:\/\/doi.org\/10.1016\/s0140-6736(10)62226-x","journal-title":"Lancet"},{"issue":"5","key":"3824_CR23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1136\/archdischild-2020-320761","volume":"106","author":"L Tveiten","year":"2021","unstructured":"Tveiten L, Diep LM, Halvorsen T, Markestad T (2021) Heart rate during the first 24 hours in term-born infants, (in eng). Arch Dis Child Fetal Neonatal Ed 106(5):489\u2013493. https:\/\/doi.org\/10.1136\/archdischild-2020-320761","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"11","key":"3824_CR24","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.echo.2024.07.007","volume":"37","author":"PM Mugaba","year":"2024","unstructured":"Mugaba PM, Hornberger LK, McBrien A, Mills L, Eckersley LG (2024) A comparison of perinatal circulatory transition in critical right and left heart obstructive lesions, (in eng). J Am Soc Echocardiogr 37(11):1073\u20131082. https:\/\/doi.org\/10.1016\/j.echo.2024.07.007","journal-title":"J Am Soc Echocardiogr"},{"issue":"5","key":"3824_CR25","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2133\/dmpk.20.337","volume":"20","author":"M Murakami","year":"2005","unstructured":"Murakami M, Furuie H, Matsuguma K, Wanibuchi A, Kikawa S, Irie S (2005) Pharmacokinetics and pharmacodynamics of landiolol hydrochloride, an ultra short-acting beta1-selective blocker, in a dose escalation regimen in healthy male volunteers, (in eng). Drug Metab Pharmacokinet 20(5):337\u2013344. https:\/\/doi.org\/10.2133\/dmpk.20.337","journal-title":"Drug Metab Pharmacokinet"},{"issue":"6","key":"3824_CR26","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1248\/cpb.40.1462","volume":"40","author":"S Iguchi","year":"1992","unstructured":"Iguchi S et al (1992) Development of a highly cardioselective ultra short-acting beta-blocker, ONO-1101, (in eng). Chem Pharm Bull (Tokyo) 40(6):1462\u20131469. https:\/\/doi.org\/10.1248\/cpb.40.1462","journal-title":"Chem Pharm Bull (Tokyo)"},{"issue":"11","key":"3824_CR27","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1007\/s12630-023-02586-0","volume":"70","author":"T Cafaro","year":"2023","unstructured":"Cafaro T et al (2023) Landiolol for the prevention of postoperative atrial fibrillation after cardiac surgery: a systematic review and meta-analysis, (in eng). Can J Anaesth 70(11):1828\u20131838","journal-title":"Can J Anaesth"},{"issue":"1","key":"3824_CR28","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/ehf2.14202","volume":"10","author":"L Schroeder","year":"2023","unstructured":"Schroeder L et al (2023) Heart rate control with landiolol hydrochloride in infants with ventricular dysfunction and pulmonary hypertension, (in eng). ESC Heart Fail 10(1):385\u2013396. https:\/\/doi.org\/10.1002\/ehf2.14202","journal-title":"ESC Heart Fail"},{"issue":"12","key":"3824_CR29","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1007\/s00228-023-03584-3","volume":"79","author":"A Chalkias","year":"2023","unstructured":"Chalkias A, O\u2019Donnell EP (2023) Mechanisms of landiolol-mediated positive inotropy in critical care settings, (in eng). Eur J Clin Pharmacol 79(12):1607\u20131612. https:\/\/doi.org\/10.1007\/s00228-023-03584-3","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"3824_CR30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/s1010-7940(01)01089-2","volume":"21","author":"A Dodge-Khatami","year":"2002","unstructured":"Dodge-Khatami A, Miller OI, Anderson RH, Gil-Jaurena JM, Goldman AP, de Leval MR (2002) Impact of junctional ectopic tachycardia on postoperative morbidity following repair of congenital heart defects, (in eng). Eur J Cardiothorac Surg 21(2):255\u2013259. https:\/\/doi.org\/10.1016\/s1010-7940(01)01089-2","journal-title":"Eur J Cardiothorac Surg"},{"issue":"12","key":"3824_CR31","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1111\/pan.14995","volume":"34","author":"M M\u00fcller","year":"2024","unstructured":"M\u00fcller M et al (2024) Perioperative anesthetic management of patients with hypoplastic left heart syndrome undergoing the comprehensive stage II surgery-a review of 148 cases, (in eng). Paediatr Anaesth 34(12):1223\u20131230. https:\/\/doi.org\/10.1111\/pan.14995","journal-title":"Paediatr Anaesth"},{"issue":"7","key":"3824_CR32","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.earlhumdev.2010.05.016","volume":"86","author":"K Michikata","year":"2010","unstructured":"Michikata K, Sameshima H, Sumiyoshi K, Kodama Y, Kaneko M, Ikenoue T (2010) Developmental changes in catecholamine requirement, volume load and corticosteroid supplementation in premature infants born at 22 to 28weeks of gestation. Early Human Dev 86(7):401\u2013405. https:\/\/doi.org\/10.1016\/j.earlhumdev.2010.05.016","journal-title":"Early Human Dev"},{"issue":"5","key":"3824_CR33","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1093\/icvts\/ivs323","volume":"15","author":"M Giglio","year":"2012","unstructured":"Giglio M, Dalfino L, Puntillo F, Rubino G, Marucci M, Brienza N (2012) Haemodynamic goal-directed therapy in cardiac and vascular surgery A systematic review and meta-analysis, (in eng). Interact Cardiovasc Thorac Surg 15(5):878\u2013887. https:\/\/doi.org\/10.1093\/icvts\/ivs323","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"3824_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euaf025","author":"I Michel-Behnke","year":"2025","unstructured":"Michel-Behnke I et al (2025) Landiolol is effective and safe in paediatric supraventricular tachycardia: Evidence from a European prospective multicentre open-label Phase III study (LANDI-PED). EP Europace. https:\/\/doi.org\/10.1093\/europace\/euaf025","journal-title":"EP Europace"},{"key":"3824_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd3020016","author":"I Nederend","year":"2016","unstructured":"Nederend I, Jongbloed MRM, de Geus EJC, Blom NA, Ten Harkel ADJ (2016) Postnatal cardiac autonomic nervous control in pediatric congenital heart disease, (in eng). J Cardiovasc Dev Dis. https:\/\/doi.org\/10.3390\/jcdd3020016","journal-title":"J Cardiovasc Dev Dis"},{"issue":"2","key":"3824_CR36","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1510\/icvts.2008.194555","volume":"9","author":"L McGlone","year":"2009","unstructured":"McGlone L, Patel N, Young D, Danton MD (2009) Impaired cardiac autonomic nervous control after cardiac bypass surgery for congenital heart disease, (in eng). Interact Cardiovasc Thorac Surg 9(2):218\u2013222. https:\/\/doi.org\/10.1510\/icvts.2008.194555","journal-title":"Interact Cardiovasc Thorac Surg"}],"container-title":["Pediatric Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00246-025-03824-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00246-025-03824-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00246-025-03824-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T09:09:24Z","timestamp":1769677764000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00246-025-03824-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["3824"],"URL":"https:\/\/doi.org\/10.1007\/s00246-025-03824-6","relation":{},"ISSN":["0172-0643","1432-1971"],"issn-type":[{"value":"0172-0643","type":"print"},{"value":"1432-1971","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,10]]},"assertion":[{"value":"20 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors Matthias M\u00fcller and Lukas Andreas Puschmann were sponsored with an unrestricted research grant from AOP Orphan Pharmaceuticals GmbH. The retrospective analysis of landiolol hydrochloride (Rapibloc\u00a9, Landiolol lyophilizate, AOP Orphan Pharmaceuticals GmbH) was conducted in cooperation with AOP Orphan Pharmaceuticals GmbH. Martin Unger, Jakob Ackerl, and Olga Shatilova are employees of AOP Orphan Pharmaceuticals GmbH, Vienna, Austria. The other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}